Repurposing the Antidiabetic Drugs Glyburide, Gliquidone, and Glipizide in Combination with Benznidazole for Trypanosoma cruzi Infection DOI Creative Commons
Citlali Vázquez,

Rusely Encalada,

Isabel Jiménez-Galicia

и другие.

Pharmaceuticals, Год журнала: 2024, Номер 18(1), С. 21 - 21

Опубликована: Дек. 27, 2024

Infection with the protozoan parasite Trypanosoma cruzi causes human Chagas disease. Benznidazole (BNZ) and nifurtimox are current drugs for treatment; however, they induce severe adverse side effects in patients; therefore, there is a need to improve treatment effectiveness efficiency of these its safer use. Background/Objective: Glyburide, glipizide, gliquidone, hypoglycemic diabetes treatment, were previously predicted bind dihydrofolate reductase-thymidylate synthase from T. by silico docking analysis; also showed antiproliferative against epimastigotes, stage insect vector. In present study, potential parasiticidal effect antidiabetic was tested monotherapy bi-therapy BNZ cells vitro animals. Methods: Evaluation performed (a) model infection trypomastigotes using fibroblasts as host (b) mice infected cruzi. Results: The antiparasitic preventing progression (trypomastigotes release), an IC50 8.4–14.3 µM comparison that (0.26 µM) vitro. However, bi-therapy, presence just 0.5 or 1 antidiabetics decreased 5–10 times 0.03–0.05 µM. Remarkably, 40–60% similar extent (80%). addition, combination plus perturbed antioxidant metabolites epimastigotes. Conclusions: These results identified therapy treat infection.

Язык: Английский

Nuevas tecnologías en ensayos preclínicos: acelerando el camino hacia terapias innovadoras DOI Creative Commons
Hugo H. Ortega, Natalia R. Salvetti

Revista Científica ANMAT, Год журнала: 2025, Номер 6, С. e81 - e81

Опубликована: Янв. 22, 2025

Процитировано

0
Repurposing the Antidiabetic Drugs Glyburide, Gliquidone, and Glipizide in Combination with Benznidazole for Trypanosoma cruzi Infection DOI Creative Commons
Citlali Vázquez,

Rusely Encalada,

Isabel Jiménez-Galicia

и другие.

Pharmaceuticals, Год журнала: 2024, Номер 18(1), С. 21 - 21

Опубликована: Дек. 27, 2024

Infection with the protozoan parasite Trypanosoma cruzi causes human Chagas disease. Benznidazole (BNZ) and nifurtimox are current drugs for treatment; however, they induce severe adverse side effects in patients; therefore, there is a need to improve treatment effectiveness efficiency of these its safer use. Background/Objective: Glyburide, glipizide, gliquidone, hypoglycemic diabetes treatment, were previously predicted bind dihydrofolate reductase-thymidylate synthase from T. by silico docking analysis; also showed antiproliferative against epimastigotes, stage insect vector. In present study, potential parasiticidal effect antidiabetic was tested monotherapy bi-therapy BNZ cells vitro animals. Methods: Evaluation performed (a) model infection trypomastigotes using fibroblasts as host (b) mice infected cruzi. Results: The antiparasitic preventing progression (trypomastigotes release), an IC50 8.4–14.3 µM comparison that (0.26 µM) vitro. However, bi-therapy, presence just 0.5 or 1 antidiabetics decreased 5–10 times 0.03–0.05 µM. Remarkably, 40–60% similar extent (80%). addition, combination plus perturbed antioxidant metabolites epimastigotes. Conclusions: These results identified therapy treat infection.

Язык: Английский

Процитировано

0